Skip to main content

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent

14 أيار 2025
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.

For more details: Click here